STOCK TITAN

Simulations Plus Sets Date for First Quarter Fiscal Year 2023 Earnings Release and Conference Call

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Simulations Plus (NASDAQ: SLP) will announce its first-quarter fiscal 2023 financial results, covering the period ended November 30, 2022, after market close on January 4, 2023. The company will host a conference call at 5 p.m. EST to discuss these results. Interested participants can register via the company's website. Simulations Plus has provided biosimulation solutions for over 25 years, supporting drug discovery and regulatory submissions across major pharmaceutical and biotech sectors.

Positive
  • Simulations Plus is a leading provider in the biosimulation market with a 25-year history.
  • The upcoming conference call will provide insights into financial results and future outlook.
Negative
  • None.

Conference call to be on Wednesday, January 4, 2023, at 5 p.m. EST

LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) announced today that it will report financial results for the first quarter of fiscal year 2023, the period ended November 30, 2022, after the close of the financial markets on Wednesday, January 4, 2023.

The Company will host a conference call on January 4, 2023, at 5 p.m. Eastern Standard Time. All interested parties are invited to join the call by registering here or by calling 1-201-389-0879. Please join five to 10 minutes before the scheduled start time. The call will be simulcast live on the Internet, and the webcast will be available on the Investors page of the Simulations Plus website under Conference Calls & Presentations. A replay of the webcast will be available on the website approximately one hour following the call.

About Simulations Plus

Serving clients worldwide for more than 25 years, Simulations Plus is a leading provider in the biosimulation market providing software and consulting services supporting drug discovery, development, research, and regulatory submissions. We offer solutions that bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on LinkedIn | Twitter | YouTube.

Environmental, Social, and Governance (ESG)

We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our ESG Report.

Simulations Plus Investor Relations

Ms. Renee Bouche

661-723-7723

renee.bouche@simulations-plus.com

Hayden IR

Mr. Brian Siegel

346-396-8696

brian@haydenir.com

Source: Simulations Plus, Inc.

FAQ

When will Simulations Plus report its Q1 FY2023 earnings?

Simulations Plus will report its Q1 FY2023 earnings on January 4, 2023, after market close.

What time is the Simulations Plus conference call scheduled for?

The conference call is scheduled for 5 p.m. EST on January 4, 2023.

How can I join the Simulations Plus conference call?

You can join the Simulations Plus conference call by registering on their website or by calling 1-201-389-0879.

What period does Simulations Plus's Q1 FY2023 financial results cover?

The Q1 FY2023 financial results cover the period ended November 30, 2022.

Simulations Plus, Inc.

NASDAQ:SLP

SLP Rankings

SLP Latest News

SLP Stock Data

629.91M
16.42M
18.14%
77.89%
4.88%
Health Information Services
Services-computer Integrated Systems Design
Link
United States of America
LANCASTER